OPSYNVI® logo

This site is intended for
U.S. healthcare professionals

I Am a Patient or Caregiver
I Am a Healthcare Professional

PATIENT PROFILES

Have you considered prescribing OPSYNVI® for some of your patients with PAH?

The 2022 ESC/ERS Guidelines recommend dual combination therapy with an ERA and PDE5i for certain patients with PAH.1* OPSYNVI® contains 2 proven therapies in 1 tablet.2-4

Started with an ERA + a PDE5i—now searching for a single-tablet alternative
Blue arrow

Erin—41-year-old, female patient

PAH etiologyIdiopathic PAH
Time since PAH diagnosis3.5 years
Current risk status
(based on ESC/ERS Guidelines)		Low
6MWD516 meters
WHO Functional Class FC II
BNP/NT-proBNPNT-proBNP 220 ng/L
Systolic blood pressure
Heart rate		118 mmHg
72 beats/min
Current PAH treatmentsERA + PDE5i
combination therapy
Notes from most recent exam:
Erin has been adherent with her current PAH regimen of ERA + PDE5i and her symptoms have remained stable.
Recently, she has expressed concern about the number of pills she takes—not just for PAH, but about the amount of pills she takes daily.

Would you transition a patient like Erin to OPSYNVI® (macitentan/tadalafil)? 1
With 1 tablet, target 2 foundational pathways, endothelin and nitric oxide.1,2

Request a Medical
Science Liaison (MSL)Contact your MSL Dark blue arrow

6MWD=6-minute walk distance; BNP=brain natriuretic peptide; ERA=endothelin receptor antagonist; ERS=European Respiratory Society; ESC=European Society of Cardiology; FC=Functional Class; NT-proBNP=N-terminal pro-brain natriuretic peptide; PAH=pulmonary arterial hypertension; PAH-CTD=PAH associated with connective tissue disease; PDE5i=phosphodiesterase type 5 inhibitor; PVR=pulmonary vascular resistance; WHO=World Health Organization.

References: 1. Humbert M, Kovacs G, Hoeper MM, et al; ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Heart J. 2022;43(38):3618-3731. 2. OPSYNVI® (macitentan/tadalafil) full Prescribing Information. Actelion Pharmaceuticals US, Inc. 3. Galiè N, Brundage BH, Ghofrani HA, et al; Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009;119(22):2894-2903. 4. Pulido T, Adzerikho I, Channick RN, Delcroix M, et al; SERAPHIN Investigators. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369(9):809-818 and suppl 1-21. doi:10.1056/NEJMoa1213917